NCT00425204

Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment

A Multi-Center, Open-Label Clinical Trial To Determine The Safety of ABX-EGF As Continued Treatment For Patients Who Have Benefited From and Tolerated Prior ABX-EGF Treatment

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: Amgen · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A multi-center, open-label, extended treatment, clinical trial examining the safety of administering multiple does of panitumumab by intravenous (i.v.) infusion to patients who have previously received panitumumab and benefited from treatment

Conditions

• Colorectal Cancer
• Non-Small Cell Lung Cancer
• Prostate Cancer
• Solid Tumors
• Advanced Renal Cell Carcinoma

Interventions

Type	Name	Description
DRUG	Panitumumab (ABX-EGF)	Dose received in previous studies will be rolled over to this study. These regimens include: 2.5 mg/kg weekly; 6.0 mg/kg every 2 weeks; and 9.0 mg/kg every 3 weeks.

Timeline

• Start date: 2004-03-01
• Primary completion: 2007-09-01
• Completion: 2008-03-01
• First posted: 2007-01-22
• Last updated: 2008-09-15